Astellas Pharma : Reports Full Year FY2016 Financial Results (462 KB)

Press Release

Astellas Reports Full Year FY2016 Financial Results

- Sales decreased (-4.4%) on a reported basis and increased approximately 2% excluding the factors associated with the transfer of the global dermatology business implemented in April 2016 and the impact of the foreign exchange; Increased core operating profit (+2.7%) and core profit (+7.3%)

• Sales of XTANDI® (enzalutamide) and overall overactive bladder ("OAB") treatments steadily increased on a constant currency basis

• Sales in the Americas, EMEA1, Asia and Oceania decreased while increased on a constant currency basis. Sales in Japan decreased due to impacting factors such as a National Health Insurance ("NHI") drug price revision

• Astellas continues to create solid and resilient growth over the mid-to-long term

  • Astellas completed the acquisition of Ganymed Pharmaceuticals AG ("Ganymed") in December 2016

  • Astellas entered into a definitive agreement under which Astellas has agreed to acquire Ogeda SA ("Ogeda") in March 2017;

The procedures required for this acquisition are still in progress (as of April 2017).

Tokyo, April 27, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") today announced the financial results for fiscal year 2016 ("FY2016") ended March 31, 2017.

"We achieved multiple milestones including the acquisition of Ganymed last December and an agreement with Ogeda shareholders to acquire Ogeda last month. These acquisitions and other alliances will expand Astellas' late-stage pipeline and contribute to its mid-to-long term growth," said Yoshihiko Hatanaka, President and CEO, Astellas. "We remain committed to creating innovative medical solutions and delivering value for patients and all stakeholders, as we continue to advance our strategic plan through maximizing the product value, creating innovation and pursuing operational excellence in the fiscal year 2017."

Consolidated Financial Results (April 1, 2016 - March 31, 2017) (core basis) (Millions of yen)

Full-Year Financial Results

Sales for the full-year of FY2016 decreased by 4.4% compared to the previous fiscal year ("year-on-year") and resulted in 1,311.7 billion yen. Sales decreased due to the impact of foreign exchange as well as the impact of the NHI drug price revision in Japan enforced in April 2016. Sales increased by approximately 2% year-on-year excluding the factors associated with the transfer of the global dermatology business implemented in April 2016 and the impact of the foreign exchange.

In terms of global products, sales of XTANDI® marginally increased and sales of overall OAB treatments Vesicare® (solifenacin succinate) and Betanis® / Myrbetriq® / BETMIGA® (mirabegron) decreased due to the impact of foreign exchange, but sales of each product steadily increased on a local currency basis. Prograf® (tacrolimus) sales also decreased.

2 >

• Sales in Japan decreased by 3.3% year-on-year to 480.8 billion yen. Sales in the Japanese market decreased by 6.3% year-on-year to 452.7 billion yen mainly due to the impact of the NHI drug price revision. Sales growth continued for products such as overall OAB treatments (Vesicare® and Betanis®), Celecox® (celecoxib), Symbicort® (budesonide and formoterol fumarate dihydrate) and Suglat® (ipragliflozin). Sales of XTANDI® decreased due to the impact of the NHI drug price

  revision. Sales of vaccines declined due to the continued impact of shipping restraints by the manufacturer in FY2015 (shipments of some of the products have already recommenced). Revenues were impacted by the decline in sales of products including Lipitor® (atorvastatin calcium) and Gaster® (famotidine) mainly due to the impact of generics.

• Sales in the Americas decreased by 9.4% year-on-year to 412.4 billion yen; however sales on a U.S. dollar basis increased by 0.5% year-on-year to 3,805 million USD. The increase in sales of CRESEMBA® (isavuconazonium sulfate) contributed to the sales growth. Sales of products including XTANDI®, overall OAB treatments (VESIcare® and Myrbetriq®) and Lexiscan® (regadenoson) decreased due to the impact of foreign exchange, while the sales of each product on a US dollar basis increased.

• EMEA saw a 0.5% increase in sales year-on-year to 330.8 billion yen, with growth driven by XTANDI®. Sales on a euro basis increased by 12.1% year-on-year to 2,785 million euros. Sales of overall OAB treatments (Vesicare® and BETMIGA®) and Prograf® declined due to the impact of foreign exchange.

• In Asia and Oceania, sales decreased by 3.8% year-on-year to 87.7 billion yen, while the sales on a constant currency basis increased by approximately 9%. XTANDI® and overall OAB treatments (Vesicare® and BETMIGA®) contributed to the revenue growth. Sales of Prograf® and Harnal® (tamsulosin hydrochloride) declined mainly due to the foreign exchange impact.

  Other Financial Highlights

  Based on the transfer of the global dermatology business in April 2016, the sales and expenses of the transferred products were not included in FY2016; however the consideration for the business transfer was recognized as revenue over certain periods. As a result, there were certain positive impacts on sales and profit in FY2016.

  Strategic Highlights in FY2016

  Astellas continues to create sustainable growth over the mid-to-long term through the pursuit of three main strategies - "Maximizing the Product Value," " Creating Innovation" and "Pursuing Operational Excellence." The company achieved multiple accomplishments throughout FY2016 including the following highlights outlined below.

  Maximizing the Product Value

• Continued to maximize the growth of the oncology franchise centered on XTANDI® and the OAB franchise comprised of Vesicare® and Betanis® / Myrbetriq® / BETMIGA® with new launches across various countries and growth in sales

• With respect to the update of the product label for XTANDI®, including the data from the head-to-head TERRAIN trial of enzalutamide versus bicalutamide, the Company obtained regulatory approvals in Europe and the U.S., and the product label was updated in April 2016 in Europe, and October 2016 in the U.S.

• Launched multiple products including Repatha® (evolocumab), PCSK9-inhibitor for the treatment of hypercholesterolemia in April 2016; Micatrio® Combination Tablets (telmisartan / amlodipine besylate / hydrochlorothiazide) for the treatment of hypertension in November 2016; Kiklin® Granules (bixalomer) for the treatment of hyperphosphatemia in December 2016; and guanylate cyclase-C receptor agonist, LINZESS (linaclotide), for the treatment of the irritable bowel syndrome with constipation in March 2017 were all launched in Japan.

Creating Innovation

• Completion of the acquisition of Ganymed.

• Definitive agreement under which Astellas has agreed to acquire Ogeda.

  The procedures required for this acquisition are still in progress (as of April 2017).

  The following list highlights alliances with external partners announced during FY2016:

• Entered into a collaborative research agreement with the National Institute of Advanced Industrial Science and Technology to discover anti-protozoan parasite drugs for the treatment of Chagas' disease in April 2016.

• Announced the conclusion of a joint research agreement with Daiichi Sankyo Company, Limited and Takeda Pharmaceutical Company Limited to comprehensively acquire and analyze fundamental biomarker data in May 2016.